このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

腎移植後の血管合併症 (DAN-PTRAIII)

2026年10月12日 更新者:University of Aarhus

腎移植後の血管合併症:前向き全国多施設共同研究 - DAN-PTRAIII研究

  • To determine the incidence of arterial inflow problems and venous outflow problems as causes of impaired renal function and/or treatment-resistant hypertension after kidney transplantation, when all kidney-transplant recipients in Denmark are evaluated according to uniform, well-defined clinical criteria.
  • To investigate the efficacy and safety of catheter-based balloon treatment (percutaneous transluminal angioplasty, PTA) for these vascular complications, of which transplant renal artery stenosis is by far the most common.
  • To assess whether novel imaging and functional diagnostic methods can predict treatment response.

調査の概要

詳細な説明

Kidney transplantation is performed 250-300 times annually in Denmark and substantially improves survival, quality of life, and reduces the burden of comorbidities in patients with end-stage kidney disease. Despite these benefits, vascular complications, particularly transplant renal artery stenosis (TRAS), remain a major cause of morbidity. Reported incidence of TRAS varies widely (1-23%), reflecting retrospective study designs and inconsistent diagnostic criteria. TRAS are classified into three main types: anastomotic (TRAS-A), post-anastomotic (TRAS-P), and long-segment bend/kink (TRAS-B), with most cases diagnosed within the first two years post-transplant. Severe stenoses can critically impair graft perfusion, leading to reduced renal function and treatment-resistant hypertension.

Percutaneous transluminal angioplasty (PTA) for TRAS is a well-established procedure performed according to the same principles as coronary balloon angioplasty; however, the role of stent placement remains uncertain. PTA without stenting is associated with higher restenosis rates compared to PTA with stenting, yet evidence regarding graft function, survival, and blood-pressure control remains conflicting.

Adverse events related to PTA occur in approximately 10% of patients and are generally mild. Serious adverse events are observed in fewer than 5% of patients and include procedure-related internal bleeding and vascular access-site complications. Severe internal bleeding may require blood transfusion and endovascular vessel occlusion and can, in rare cases, result in loss of the transplanted kidney. Access-site vascular complications may present as bleeding, thrombosis, or pseudoaneurysm.

Against this background, the nationwide prospective multicentre DAN-PTRAIII study aims to establish the true incidence of arterial inflow and venous outflow problems in Danish kidney-transplant recipients, evaluate the efficacy and safety of balloon angioplasty, and explore novel imaging and functional diagnostic methods for predicting treatment response.

研究の種類

観察的

入学 (推定)

60

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

  • 名前:Mark Reinhard, MD, PhD
  • 電話番号:+45 40460321
  • メール:markrein@rm.dk

研究連絡先のバックアップ

研究場所

      • Aarhus、デンマーク、8200
        • 募集
        • Aarhus University Hospital
        • コンタクト:
      • Copenhagen、デンマーク、2100
      • Odense、デンマーク、5000
        • 募集
        • Odense University Hospital
        • コンタクト:

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

サンプリング方法

非確率サンプル

調査対象母集団

National prospective multicenter study with a primary endpoint at 3 months and annual follow-up for up to 10 years post-intervention, evaluating renal function, blood pressure, and clinical events.

Patients with vascular complications, predominantly transplant renal artery stenosis (TRAS) following kidney transplantation, who meet at least one of the clinical inclusion criteria, may be enrolled in the study.

説明

Inclusion Criteria:

1. At least one of the following clinical criteria (1 or 2) must be fulfilled:

  1. Graft dysfunction, defined by at least one of the following:

    • Acute reduction in estimated glomerular filtration rate (eGFR) >15% on two consecutive measurements at least 2 weeks apart, with other causes excluded (rejection, obstruction, infection).
    • eGFR <50% of the expected value 30 days after kidney transplantation of unknown cause.
    • Decline in eGFR >30% after initiation of an angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker.
  2. Persistent resistant hypertension for more than 6 weeks after kidney transplantation, defined as:

    • 24-hour ambulatory systolic blood pressure >130 mmHg despite treatment with at least three classes of antihypertensive medication at maximally tolerated doses (including diuretics, if tolerated).

Together with at least one of the following radiological criteria:

  1. CT or MR angiography demonstrating a lumen reduction ≥50%.

  2. Doppler ultrasound showing:

    1. Peak systolic velocity in the renal artery ≥200 cm/s and a renal-renal ratio (velocity at stenosis / velocity in distal artery) >4.
    2. Acceleration time >70 ms in intrarenal arteries.

2. In cases of strong clinical suspicion of a vascular complication where CT or MR angiography cannot reliably exclude graft artery or vein stenosis, patients may be referred for confirmatory invasive investigations.

Before PTA, catheter-based angiography and translesional pressure measurements are performed to confirm whether the patient meets the radiological eligibility criterion for PTA:

  1. Stenosis ≥70%.

  2. Stenosis 50-69% if at least one of the following criteria is met:

    • Mean translesional pressure gradient ≥10 mmHg.
    • Systolic pressure gradient ≥20 mmHg.
    • Renal Pd/Pa ≤0.8.
    • If pressure measurements cannot be obtained, treatment is based on the operator's clinical judgement.

Exclusion Criteria:

  1. Inability to provide informed consent.
  2. Concurrent biopsy demonstrating rejection requiring treatment.
  3. Pregnancy.
  4. Previous PTA of the same vessel.
  5. Patients unable to tolerate any form of antithrombotic therapy and therefore not eligible for stent placement.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 観測モデル:COHORT
  • 時間の展望:PROSPECTIVE

コホートと介入

グループ/コホート
介入・治療
Kidney Transplant Recipients

Patients who meet well-defined clinical and radiological criteria for significant vascular complications after kidney transplantation, with transplant renal artery stenosis being by far the most common.

Catheter-based angiography performed in accordance with the study protocol.

Measurement of translesional pressure gradients performed in accordance with the study protocol.

Intravascular ultrasound (IVUS) performed in accordance with the study protocol.

Percutaneous transluminal angioplasty (PTA) is performed in accordance with the study protocol. As a general principle, bare-metal stents (BMS) are used. Drug-eluting stents (DES) may be considered when the arterial lumen diameter is < 4-5 mm. In stenoses where stent placement carries a risk of side-branch occlusion, PTA is performed without stent implantation and most often with a drug-coated balloon (DCB).

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Change in measured glomerular filtration rate (mGFR).
時間枠:Baseline and 3 months post-PTA.

Change in measured glomerular filtration rate (mGFR) at 3 months post-PTA compared with baseline.

Baseline and 3 months post-PTA.

二次結果の測定

結果測定
メジャーの説明
時間枠
Change in estimated glomerular filtration rate (eGFR).
時間枠:Baseline, Day 1, Day 7, Day 21, 6 weeks, 3 months, 12 months, and annually thereafter for up to 10 years post-PTA.

Change in estimated glomerular filtration rate (eGFR) measured on day 1, day 7, day 21, at 6 weeks, at 3 and 12 months, and annually thereafter for up to 10 years post-PTA, compared with baseline.

Baseline, Day 1, Day 7, Day 21, 6 weeks, 3 months, 12 months, and annually thereafter for up to 10 years post-PTA.
Change in home systolic blood pressure.
時間枠:Baseline, Day 7, Day 21, 6 weeks, 3 months, 12 months, and annually thereafter for up to 10 years post-PTA.

Change in home systolic blood pressure measured on day 7, day 21, at 6 weeks, at 3 and 12 months, and annually thereafter for up to 10 years post-PTA, compared with baseline.

Baseline, Day 7, Day 21, 6 weeks, 3 months, 12 months, and annually thereafter for up to 10 years post-PTA.
Change in attended automated office systolic blood pressure.
時間枠:Baseline, 3 months, 12 months, and 24 months post-PTA.

Change in attended automated office systolic blood pressure measured at 3, 12, and 24 months post-PTA, compared with baseline.

Baseline, 3 months, 12 months, and 24 months post-PTA.
Change in unattended automated office systolic blood pressure.
時間枠:Baseline, 3 months, 12 months, and 24 months post-PTA.

Change in unattended automated office systolic blood pressure measured at 3, 12, and 24 months post-PTA, compared with baseline.

Baseline, 3 months, 12 months, and 24 months post-PTA.
Change in 24-hour ambulatory systolic blood pressure.
時間枠:Baseline, 3 months, 12 months, and 24 months post-PTA.

Change in 24-hour ambulatory systolic blood pressure measured at 3, 12, and 24 months post-PTA, compared with baseline.

Baseline, 3 months, 12 months, and 24 months post-PTA.
Change in defined daily dose (DDD) of antihypertensive medications.
時間枠:Baseline, 3 months, 12 months, and 24 months post-PTA.

Change in defined daily dose (DDD) of antihypertensive medications at 3, 12, and 24 months post-PTA compared with baseline.

Baseline, 3 months, 12 months, and 24 months post-PTA.
Change in the number of antihypertensive medications.
時間枠:Baseline, 3 months, 12 months, and 24 months post-PTA.

Change in the number of antihypertensive medications at 3, 12, and 24 months post-PTA compared with baseline.

Baseline, 3 months, 12 months, and 24 months post-PTA.
Change in 24-hour ambulatory systolic blood pressure adjusted for changes in antihypertensive medication.
時間枠:Baseline, 3 months, 12 months, and 24 months post-PTA.

Change in 24-hour ambulatory systolic blood pressure measured at 3, 12, and 24 months post-PTA, compared with baseline, adjusted for changes in antihypertensive medication (5 mmHg per DDD).

Baseline, 3 months, 12 months, and 24 months post-PTA.
Health status on 12-item Short Form Health Survey (SF-12).
時間枠:Baseline and 3 months post-PTA.

Change in 12-item Short Form Health Survey (SF-12) scores at 3 months post-PTA, compared with baseline.

Scores range from 0 to 100, with higher scores indicating better physical and mental health functioning.

Baseline and 3 months post-PTA.
Number of clinical events after PTA.
時間枠:10 years post-PTA.

Cardiovascular and renal events are defined according to the criteria used in the DAPA-CKD study, with the modification that end-stage kidney disease is defined exclusively as either kidney transplantation or chronic dialysis. After PTA treatment, the following clinical events will be recorded for 10 years:

  1. Cardiovascular death
  2. Renal death
  3. Death from non-cardiovascular and non-renal causes
  4. Undetermined cause of death
  5. Stroke
  6. Myocardial infarction
  7. Hospitalization for heart failure
  8. Reduction in eGFR ≥50% from baseline for ≥28 days, not fulfilling the definition of end-stage kidney disease
  9. End-stage kidney disease, defined as kidney transplantation or chronic dialysis for ≥28 days
  10. Biopsy-proven rejection
  11. Need for repeat PTA due to restenosis or in-stent thrombosis
  12. Other relevant clinical events
10 years post-PTA.
Number of adverse events (AEs) occurring within 30 days after the procedure
時間枠:30 days post-PTA.

All adverse events (AEs) occurring within 30 days after the procedure will be recorded and classified according to seriousness, relationship to the procedure, and whether the event occurs within ≤24 hours (periprocedural) or >24 hours through day 30 (post-interventional):

  1. Vessel rupture
  2. Vessel dissection
  3. Vessel occlusion
  4. Vessel perforation
  5. Stent thrombosis
  6. Embolic events to the kidney or the peripheral circulation (upper or lower extremity, depending on the access route)
  7. Pulmonary oedema
  8. Major bleeding requiring transfusion
  9. Embolisation due to bleeding or another adverse event
  10. Nephrectomy due to bleeding or another adverse event
  11. Access-site or access-vessel complication requiring additional hospitalisation, blood transfusion, or surgical intervention
  12. Requirement for acute dialysis
  13. Clinical events, including all-cause mortality, as defined above
  14. Other relevant adverse events (AEs)
30 days post-PTA.
Doppler ultrasound.
時間枠:Baseline and 3 months post-PTA.

Diagnostic utility and predictive value for treatment response to PTA.

Baseline and 3 months post-PTA.
Invasive pressure measurements across stenoses.
時間枠:Baseline and 3 months post-PTA.

Diagnostic utility and predictive value for treatment response to PTA.

Baseline and 3 months post-PTA.
Intravascular ultrasound.
時間枠:Baseline and 3 months post-PTA.

Diagnostic utility and predictive value for treatment response to PTA.

Baseline and 3 months post-PTA.
Non-invasive fractional flow reserve computed tomography (FFR-CT) / computational fluid dynamics (CFD) simulation.
時間枠:Baseline and 3 months post-PTA.

Diagnostic utility and predictive value for treatment response to PTA.

Baseline and 3 months post-PTA.
Functional magnetic resonance imaging.
時間枠:Baseline and 3 months post-PTA.

Diagnostic utility and predictive value for treatment response to PTA.

Baseline and 3 months post-PTA.

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2026年5月22日

一次修了 (推定)

2031年3月31日

研究の完了 (推定)

2031年6月1日

試験登録日

最初に提出

2026年4月1日

QC基準を満たした最初の提出物

2026年4月13日

最初の投稿 (実際)

2026年4月15日

学習記録の更新

投稿された最後の更新 (実際)

2026年10月16日

QC基準を満たした最後の更新が送信されました

2026年10月12日

最終確認日

2026年5月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する